Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1707922 | 0.84 | NNMT (0.43) | NNMTCYP2A6MKNK1MKNK2KDM4E | |
| SCHEMBL12374180 | 0.81 | MAPT (0.49) | MAPTNPC1ALDH1A1 | |
| SCHEMBL3816388 | 0.79 | NNMT (0.48) | NNMTCYP2A6MKNK1MKNK2KDM4E | |
| SCHEMBL29525223 | 0.79 | NNMT (0.48) | NNMTCYP2A6MKNK1MKNK2KDM4E | |
| SCHEMBL14664943 | 0.76 | KMT2A (0.42) | CHRNB2CHRNA4MAPTKMT2A | |
| SCHEMBL15449517 | 0.76 | CHRNB2 (0.36) | CHRNB2CHRNA4 | |
| Water SCHEMBL28722139 | 0.74 | KMT2A (0.41) | CHRNB2CHRNA4MAPTKMT2A | |
| SCHEMBL17678791 | 0.74 | MAPK1 (0.30) | — | |
| SCHEMBL12363696 | 0.74 | FTO (0.40) | — | |
| SCHEMBL31026422 | 0.73 | NNMT (0.44) | NNMTCYP2A6MKNK1MKNK2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9775840-B2 | Peripherally acting opioid compounds | ALKERMES, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| US-9630947-B2 | Therapeutic compounds and related methods of use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-04-25 | — | — | US | disclosed |
| US-20170007609-A1 | PERIPHERALLY ACTING OPIOID COMPOUNDS | ALKERMES INC (US) | 2017-01-12 | — | — | US | disclosed |
| US-9415045-B2 | Peripherally acting opioid compounds | ALKERMES, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9290450-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20160009693-A1 | HERBICIDAL COMPOUNDS | SYNGENTA LIMITED (GB) | 2016-01-14 | — | — | US | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| US-20150196550-A1 | Peripherally Acting Opioid Compounds | ALKERMES INC (US) | 2015-07-16 | — | — | US | disclosed |
| US-9073890-B2 | Therapeutic compounds and related methods of use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| US-8415469-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130005755-A1 | Peripherally Acting Opioid Compounds | ALKERMES, INC. | 2013-01-03 | — | — | US | disclosed |
| US-8304413-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20110189192-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-04 | — | — | US | disclosed |
| US-7939549-B2 | 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-10 | — | — | US | disclosed |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20090318455-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20070191374-A1 | Substituted cinnolin-4-ylamines | NEUROGEN COROPERATION (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150196550-A1 | Peripherally Acting Opioid Compounds | OPRM1, OPRK1, OPRL1 | NNMT 1676/4885CYP2A6 142/4885MKNK1 3833/4885 |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | NNMT 329/4885CYP2A6 4408/4885MKNK1 598/4885 |
| US-20070191374-A1 | Substituted cinnolin-4-ylamines | CNR1, GPR174, CNR2 | NNMT 2028/4885CYP2A6 1975/4885MKNK1 3633/4885 |
| US-20170007609-A1 | PERIPHERALLY ACTING OPIOID COMPOUNDS | OPRM1, OPRK1, OPRL1 | NNMT 1676/4885CYP2A6 142/4885MKNK1 3833/4885 |
| US-20160009693-A1 | HERBICIDAL COMPOUNDS | DDT, HAX1, CYP4X1 | NNMT 3102/4885CYP2A6 139/4885MKNK1 4208/4885 |
| US-20110189192-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | NNMT 2220/4885CYP2A6 2015/4885MKNK1 70/4885 |
| US-20090318455-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | MAP3K8, MAP3K1, MAP3K6 | NNMT 1116/4885CYP2A6 3092/4885MKNK1 51/4885 |
| US-20130005755-A1 | Peripherally Acting Opioid Compounds | OPRM1, OPRK1, OPRL1 | NNMT 1676/4885CYP2A6 142/4885MKNK1 3833/4885 |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | NNMT 817/4885CYP2A6 4605/4885MKNK1 107/4885 |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | NNMT 1078/4885CYP2A6 4152/4885MKNK1 368/4885 |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PPP3CB, PTPRG | NNMT 508/4885CYP2A6 4388/4885MKNK1 365/4885 |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | NNMT 329/4885CYP2A6 4408/4885MKNK1 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.